Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Anti-integrin therapy for multiple sclerosis.
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.
The role of mitochondria in axonal degeneration and tissue repair in MS.
Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis.
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system.
Tumor-like multiple sclerosis.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
The benefits of exercise training in multiple sclerosis.
Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles.
TAPP1 inhibits the differentiation of oligodendrocyte precursor cells via suppressing the Mek/Erk pathway.
Trial watch: Chemotherapy with immunogenic cell death inducers.
[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].
MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Product Insert, Amiloride HCl Tablets
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
Naltrexone
Pages
« first
‹ previous
…
127
128
129
130
131
132
133
134
135
…
next ›
last »